Furthermore, evidence from molecular and pharmacological genetics studies in CDK12-KI/PyMT mouse tumors and human breast cancer PDX models revealed that targeting SGOC metabolism is a selective strategy to counteract CDK12-induced tumorigenesis and metastatic spreading. Here, CDK12 is linked to breast carcinoma.